YLPM1

Summary

YLPM1 (YLP motif containing 1, HGNC:17798) is a protein-coding gene on chromosome 14q24.3, encoding YLP motif-containing protein 1 (P49750). Plays a role in the reduction of telomerase activity during differentiation of embryonic stem cells by binding to the core promoter of TERT and controlling its down-regulation.

Enables RNA binding activity. Predicted to be involved in regulation of telomere maintenance. Predicted to act upstream of or within negative regulation of transcription by RNA polymerase II. Located in nuclear speck.

Source: NCBI Gene 56252 — RefSeq curated summary.

At a glance

• GWAS associations: 10
• Clinical variants (ClinVar): 396 total
• MANE Select transcript: NM_019589

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17798
Approved symbol	YLPM1
Name	YLP motif containing 1
Location	14q24.3
Locus type	gene with protein product
Status	Approved
Aliases	ZAP, PPP1R169
Ensembl gene	ENSG00000119596
Ensembl biotype	protein_coding
OMIM	619766
Entrez	56252

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 5 protein_coding, 2 protein_coding_CDS_not_defined, 2 retained_intron, 1 nonsense_mediated_decay

ENST00000325680, ENST00000546901, ENST00000547879, ENST00000549197, ENST00000549293, ENST00000550021, ENST00000552421, ENST00000553381, ENST00000554107, ENST00000930604

RefSeq mRNA: 2 — MANE Select: NM_019589 NM_001411052, NM_019589

CCDS: CCDS45135, CCDS91906

Canonical transcript exons

ENST00000325680 — 21 exons

Exon	Start	End
ENSE00000808228	74778447	74778683
ENSE00000808232	74802556	74802676
ENSE00000808234	74809910	74810002
ENSE00000808235	74810225	74810420
ENSE00000808237	74812628	74812782
ENSE00000808238	74816203	74816265
ENSE00000808240	74816931	74817107
ENSE00000808241	74817194	74817277
ENSE00000941151	74797580	74799697
ENSE00000941152	74809380	74809797
ENSE00001196204	74816571	74816690
ENSE00001196249	74811620	74811738
ENSE00001598597	74780405	74780584
ENSE00001669522	74781334	74782325
ENSE00003503487	74835265	74835447
ENSE00003600427	74829213	74829343
ENSE00003614894	74824256	74824307
ENSE00003701536	74818231	74818314
ENSE00003701614	74821057	74821137
ENSE00003717512	74835775	74837318
ENSE00003848055	74763316	74764362

Expression profiles

Bgee: expression breadth ubiquitous, 290 present calls, max score 96.47.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 41.0216 / max 434.1932, expressed in 1817 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
140580	39.8582	1816
140579	0.7700	442
140584	0.3933	164

Top tissues by expression

294 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ganglionic eminence	UBERON:0004023	96.47	gold quality
cortical plate	UBERON:0005343	96.34	gold quality
tendon of biceps brachii	UBERON:0008188	95.95	gold quality
sural nerve	UBERON:0015488	95.90	gold quality
sperm	CL:0000019	95.62	gold quality
ventricular zone	UBERON:0003053	95.60	gold quality
right uterine tube	UBERON:0001302	95.44	gold quality
male germ cell	CL:0000015	95.39	gold quality
left ovary	UBERON:0002119	95.31	gold quality
right ovary	UBERON:0002118	95.17	gold quality
medial globus pallidus	UBERON:0002477	94.76	gold quality
adrenal tissue	UBERON:0018303	94.71	gold quality
right hemisphere of cerebellum	UBERON:0014890	94.53	gold quality
tibial nerve	UBERON:0001323	94.29	gold quality
cerebellar hemisphere	UBERON:0002245	94.27	gold quality
body of uterus	UBERON:0009853	94.18	gold quality
endocervix	UBERON:0000458	94.14	gold quality
cerebellar cortex	UBERON:0002129	94.09	gold quality
globus pallidus	UBERON:0001875	94.02	gold quality
corpus callosum	UBERON:0002336	94.02	gold quality
tendon	UBERON:0000043	94.00	gold quality
stromal cell of endometrium	CL:0002255	93.94	gold quality
ovary	UBERON:0000992	93.94	gold quality
calcaneal tendon	UBERON:0003701	93.87	gold quality
colonic epithelium	UBERON:0000397	93.81	gold quality
embryo	UBERON:0000922	93.79	gold quality
endothelial cell	CL:0000115	93.71	gold quality
mucosa of stomach	UBERON:0001199	93.62	gold quality
ectocervix	UBERON:0012249	93.47	gold quality
right frontal lobe	UBERON:0002810	93.42	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	9.25
E-MTAB-9801	yes	5.79

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

104 targeting YLPM1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-6856-5P	100.00	65.47	1298
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-144-3P	99.94	73.98	2698
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-548AE-3P	99.93	72.66	4867

Literature-anchored findings (GeneRIF, showing 1)

• ZAP3 is a putative nucleoside kinase that targets protein phosphatase-1 through its highly conserved carboxy-terminal RVRW sequence. (PMID:17890166)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	ylpm1	ENSDARG00000043680
mus_musculus	Ylpm1	ENSMUSG00000021244
rattus_norvegicus	Ylpm1	ENSRNOG00000027317
drosophila_melanogaster	ZAP3	FBGN0052685

Protein

Protein identifiers

YLP motif-containing protein 1 — P49750 (reviewed: P49750)

Alternative names: Nuclear protein ZAP3, ZAP113

All UniProt accessions (5): P49750, F8VU51, H0YI23, H0YIQ2, U3KQT9

UniProt curated annotations — full annotation on UniProt →

Function. Plays a role in the reduction of telomerase activity during differentiation of embryonic stem cells by binding to the core promoter of TERT and controlling its down-regulation.

Subunit / interactions. Interacts with PPP1CA and NCOA5. Forms a complex with ILF2, ILF3, KHDRBS1, RBMX, NCOA5 and PPP1CA.

Subcellular location. Nucleus. Nucleus speckle.

Tissue specificity. Expressed in neuronal, neuroblastoma and embryonic kidney cell lines (at protein level).

Isoforms (3)

UniProt ID	Names	Canonical?
P49750-4	4	yes
P49750-3	3
P49750-1	1

RefSeq proteins (2): NP_001397981, NP_062535* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR026314	YLP_motif_con_p1	Family
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR058903	Spectrin_YLPM1-like	Domain

Pfam: PF13671, PF26583

UniProt features (73 total): compositionally biased region 41, region of interest 8, modified residue 8, cross-link 7, sequence conflict 5, splice variant 3, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P49750-F1	43.79	0.02

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (15): 735, 756, 814, 829, 831, 1100, 1119, 1402, 891, 983, 983, 1053, 1053, 1652, 1710

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 112 (showing top): GOBP_CHROMOSOME_ORGANIZATION, BROWNE_HCMV_INFECTION_6HR_DN, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, GOBP_TELOMERE_ORGANIZATION, GOBP_REGULATION_OF_TELOMERE_MAINTENANCE, chr14q24, BROWNE_HCMV_INFECTION_24HR_DN, GOBP_REGULATION_OF_CHROMOSOME_ORGANIZATION, MARKEY_RB1_ACUTE_LOF_UP, IVANOVA_HEMATOPOIESIS_EARLY_PROGENITOR, GOCC_NUCLEAR_SPECK, GOCC_NUCLEAR_BODY, GOCC_RIBONUCLEOPROTEIN_GRANULE, MARSON_BOUND_BY_FOXP3_UNSTIMULATED, MARSON_BOUND_BY_E2F4_UNSTIMULATED

GO Biological Process (1): regulation of telomere maintenance (GO:0032204)

GO Molecular Function (2): RNA binding (GO:0003723), protein binding (GO:0005515)

GO Cellular Component (2): nucleus (GO:0005634), nuclear speck (GO:0016607)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
telomere maintenance	1
regulation of chromosome organization	1
regulation of DNA metabolic process	1
nucleic acid binding	1
binding	1
intracellular membrane-bounded organelle	1
nuclear ribonucleoprotein granule	1

Protein interactions and networks

STRING

1054 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
YLPM1	RBMX	P38159	581
YLPM1	ZNF318	Q5VUA4	557
YLPM1	AREL1	O15033	548
YLPM1	PROX2	Q3B8N5	521
YLPM1	BPIFB2	Q8N4F0	486
YLPM1	DVL3	Q92997	485
YLPM1	RBM12B	Q8IXT5	473
YLPM1	KHDRBS1	Q07666	469
YLPM1	RAPH1	Q70E73	468
YLPM1	GPHN	Q9NQX3	462
YLPM1	WDR3	Q9UNX4	441
YLPM1	RPS6KL1	Q9Y6S9	437
YLPM1	VRTN	Q9H8Y1	430
YLPM1	LUC7L3	O95232	427
YLPM1	HEATR1	Q9H583	425

IntAct

137 interactions, top by confidence:

A	B	Type	Score
PPP1CB	CCDC85C	psi-mi:“MI:0914”(association)	0.750
PPP1CB	CCDC85C	psi-mi:“MI:2364”(proximity)	0.750
PPP1CC	CCDC85C	psi-mi:“MI:0914”(association)	0.740
PPP1CC	CCDC85C	psi-mi:“MI:2364”(proximity)	0.740
PPP1CA	YLPM1	psi-mi:“MI:0915”(physical association)	0.690
PPP1CA	CCDC85C	psi-mi:“MI:0914”(association)	0.670
PPP1CA	CCDC85C	psi-mi:“MI:2364”(proximity)	0.670
MAGEE1	MCC	psi-mi:“MI:0914”(association)	0.670
NCK2	SH3PXD2B	psi-mi:“MI:0914”(association)	0.640
P4HA3	FAM171A2	psi-mi:“MI:0914”(association)	0.640
KPNA1	TCERG1	psi-mi:“MI:0914”(association)	0.640
NCKIPSD	GEMIN2	psi-mi:“MI:0914”(association)	0.640
HNRNPD	HNRNPDL	psi-mi:“MI:0914”(association)	0.560
YLPM1	PPP1CC	psi-mi:“MI:0915”(physical association)	0.550
PCGF1	CBX4	psi-mi:“MI:0914”(association)	0.530
NAGK	ZBTB43	psi-mi:“MI:0914”(association)	0.530
ZFC3H1	HNRNPCL1	psi-mi:“MI:0914”(association)	0.530
NONO	YLPM1	psi-mi:“MI:0915”(physical association)	0.520
YLPM1	CACNA1A	psi-mi:“MI:0915”(physical association)	0.510
CACNA1A	YLPM1	psi-mi:“MI:0915”(physical association)	0.510
CPSF6	DDX39A	psi-mi:“MI:0914”(association)	0.480
SRGAP2	YLPM1	psi-mi:“MI:0407”(direct interaction)	0.440

BioGRID (223): YLPM1 (Affinity Capture-MS), YLPM1 (Affinity Capture-MS), YLPM1 (Affinity Capture-MS), YLPM1 (Affinity Capture-MS), YLPM1 (Affinity Capture-MS), SMARCC1 (Co-fractionation), SMARCC2 (Co-fractionation), YLPM1 (Co-fractionation), YLPM1 (Proximity Label-MS), YLPM1 (Affinity Capture-MS), YLPM1 (Affinity Capture-MS), YLPM1 (Affinity Capture-MS), YLPM1 (Affinity Capture-MS), YLPM1 (Affinity Capture-MS), YLPM1 (Affinity Capture-MS)

ESM2 similar proteins: A0A1B0GVQ3, A0A1W2PPK0, A0A1W2PPM1, A2A9I7, A6NCI8, A6QQS3, A7XCE8, E9PI22, E9PXT9, O15016, O91083, P09414, P0DMB1, P17923, P18804, P20879, P35965, P49750, Q0P670, Q12857, Q1RMX6, Q32LN6, Q32MG2, Q3B8N5, Q3T016, Q3V0A6, Q4JK59, Q5BI31, Q5T035, Q5ZKH6, Q642A3, Q6AXV6, Q6IMN6, Q6P1W5, Q6PEX7, Q6X4T0, Q80YD3, Q86UF4, Q8BII1, Q8C5V0

Diamond homologs: P0CB49, P49750, Q9R0I7

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 171 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
mRNA Polyadenylation	23	16.4×	2e-19
Dengue Virus Genome Translation and Replication	5	12.9×	3e-03
mRNA Splicing - Minor Pathway	7	12.7×	1e-04
Processing of Capped Intron-Containing Pre-mRNA	19	12.7×	9e-14
mRNA Splicing - Major Pathway	27	12.0×	2e-19
mRNA Splicing	13	11.6×	1e-08
RHOU GTPase cycle	5	11.3×	5e-03
mRNA 3’-end processing	7	11.2×	2e-04

GO biological processes:

GO term	Partners	Fold	FDR
negative regulation of mRNA splicing, via spliceosome	6	29.8×	8e-06
U2-type prespliceosome assembly	5	20.3×	5e-04
mRNA splicing, via spliceosome	23	13.7×	8e-17
autophagosome maturation	6	13.7×	5e-04
regulation of circadian rhythm	8	13.5×	2e-05
regulation of alternative mRNA splicing, via spliceosome	8	12.7×	3e-05
mitophagy	6	12.4×	8e-04
RNA processing	7	9.9×	6e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

396 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	343
Likely benign	12
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

3125 predictions. Top by Δscore:

Variant	Effect	Δscore
14:74778439:T:A	acceptor_gain	1.0000
14:74778443:GTA:G	acceptor_loss	1.0000
14:74778445:A:AG	acceptor_gain	1.0000
14:74778445:A:C	acceptor_loss	1.0000
14:74778445:AG:A	acceptor_gain	1.0000
14:74778446:G:GG	acceptor_gain	1.0000
14:74778446:GG:G	acceptor_gain	1.0000
14:74778446:GGA:G	acceptor_gain	1.0000
14:74778648:G:GT	donor_gain	1.0000
14:74778681:CAGG:C	donor_loss	1.0000
14:74778682:AGGT:A	donor_loss	1.0000
14:74778684:G:GA	donor_loss	1.0000
14:74778685:T:G	donor_loss	1.0000
14:74780397:A:AG	acceptor_gain	1.0000
14:74780398:T:G	acceptor_gain	1.0000
14:74780400:TTTA:T	acceptor_loss	1.0000
14:74780400:TTTAG:T	acceptor_gain	1.0000
14:74780401:TTAGT:T	acceptor_gain	1.0000
14:74780402:TAG:T	acceptor_gain	1.0000
14:74780403:A:AG	acceptor_gain	1.0000
14:74780403:A:T	acceptor_loss	1.0000
14:74780403:AG:A	acceptor_gain	1.0000
14:74780403:AGTCT:A	acceptor_gain	1.0000
14:74780404:G:GG	acceptor_gain	1.0000
14:74780404:G:T	acceptor_gain	1.0000
14:74780404:GT:G	acceptor_gain	1.0000
14:74780404:GTC:G	acceptor_gain	1.0000
14:74780404:GTCT:G	acceptor_gain	1.0000
14:74780404:GTCTG:G	acceptor_gain	1.0000
14:74780405:TCTG:T	acceptor_gain	1.0000

AlphaMissense

13992 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
14:74763680:T:C	L64P	1.000
14:74799640:T:A	L1448H	1.000
14:74799655:A:C	H1453P	1.000
14:74799661:T:G	I1455S	1.000
14:74799664:T:A	I1456N	1.000
14:74799664:T:C	I1456T	1.000
14:74799664:T:G	I1456S	1.000
14:74799667:T:C	L1457S	1.000
14:74799672:G:C	A1459P	1.000
14:74799673:C:A	A1459D	1.000
14:74799675:G:C	A1460P	1.000
14:74799685:T:C	L1463P	1.000
14:74799697:G:C	R1467P	1.000
14:74816207:T:A	V1836D	1.000
14:74816210:T:A	V1837D	1.000
14:74816213:T:A	I1838K	1.000
14:74816213:T:G	I1838R	1.000
14:74816221:G:A	G1841R	1.000
14:74816221:G:C	G1841R	1.000
14:74816222:G:A	G1841E	1.000
14:74816222:G:T	G1841V	1.000
14:74816230:G:C	G1844R	1.000
14:74816231:G:A	G1844D	1.000
14:74816237:G:A	G1846E	1.000
14:74816249:T:A	V1850D	1.000
14:74816258:T:C	L1853P	1.000
14:74816264:G:C	R1855P	1.000
14:74816602:C:A	P1866H	1.000
14:74816611:T:C	L1869P	1.000
14:74816620:A:T	D1872V	1.000

dbSNP variants (sampled 300 via entrez): RS1000047216 (14:74762751 A>G), RS1000173073 (14:74814632 T>C,G), RS1000179794 (14:74810932 T>G), RS1000205600 (14:74765952 C>A), RS1000219731 (14:74773039 G>A), RS1000250282 (14:74775908 A>C,T), RS1000318046 (14:74765670 C>T), RS1000322946 (14:74775565 A>T), RS1000405714 (14:74813582 T>C), RS1000444212 (14:74779002 G>A), RS1000480305 (14:74769251 A>C,G,T), RS1000547361 (14:74771666 A>G), RS1000581507 (14:74774336 G>A,T), RS1000615630 (14:74808779 G>A), RS1000654880 (14:74773967 C>T)

Disease associations

OMIM: gene MIM:619766 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): myoepithelial tumor (MONDO:0002380)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

10 associations (top):

Study	Trait	p-value
GCST004603_139	Platelet count	5.000000e-09
GCST005237_3	Mood instability	1.000000e-06
GCST005238_3	Mood instability	3.000000e-09
GCST006976_18	Macular thickness	4.000000e-25
GCST007709_128	General factor of neuroticism	2.000000e-11
GCST007709_130	General factor of neuroticism	1.000000e-09
GCST010241_69	Apolipoprotein A1 levels	5.000000e-14
GCST90000514_22	Gastroesophageal reflux disease	2.000000e-09
GCST90002400_138	Plateletcrit	2.000000e-13
GCST90002402_192	Platelet count	2.000000e-12

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0004309	platelet count
EFO:0008475	mood instability measurement
EFO:0007660	neuroticism measurement
EFO:0004614	apolipoprotein A 1 measurement
EFO:0007985	platelet crit

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D009208	Myoepithelioma	C04.557.435.585

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

35 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases expression	3
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression, decreases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
FR900359	affects phosphorylation	1
TAK-243	decreases sumoylation	1
dicrotophos	increases expression	1
triphenyl phosphate	affects expression	1
sodium arsenate	decreases expression	1
titanium dioxide	decreases methylation	1
arsenite	decreases reaction, affects binding	1
sodium arsenite	affects cotreatment, decreases expression, increases abundance	1
cobaltous chloride	decreases expression	1
butyraldehyde	decreases expression	1
manganese chloride	decreases expression, increases abundance, affects cotreatment	1
di-n-butylphosphoric acid	affects expression	1
dorsomorphin	affects cotreatment, decreases expression	1
bisphenol S	affects expression	1
LDN 193189	affects cotreatment, increases expression	1
Arsenic Trioxide	increases expression	1
Vorinostat	decreases expression	1
Arsenic	affects cotreatment, decreases expression, increases abundance	1
Caffeine	decreases phosphorylation	1
Cisplatin	decreases expression	1
Doxorubicin	decreases expression	1
Enzyme Inhibitors	increases O-linked glycosylation, decreases activity	1
Ivermectin	decreases expression	1
Manganese	decreases expression, increases abundance, affects cotreatment	1
Mercuric Chloride	decreases expression	1
Ribonucleotides	affects binding	1
Selenium	decreases expression	1

Clinical trials (associated diseases)

5 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT03600649	PHASE1	UNKNOWN	Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas
NCT05266196	PHASE1/PHASE2	UNKNOWN	A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)
NCT06239272	PHASE1/PHASE2	RECRUITING	NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
NCT06625190	PHASE1/PHASE2	RECRUITING	Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
NCT06244420	Not specified	COMPLETED	Malignant Myoepithelioma of Bone and Soft Tissues: Diagnostic Imaging and Histology in Relation to Prognosis